Impulse Device Improves Long-Term Survival in Heart Failure Patients

A long-term follow-up study of chronic heart failure patients treated with cardiac contractility modulation (CCM) has been published online in the International Journal of Cardiology. Those receiving CCM experienced significantly improved long-term survival compared with matched patients who did not receive CCM.

In the analysis, 41 heart failure patients treated with CCM were followed for approximately six years and were compared with a matched group of 41 heart failure patients derived from a registry at the same hospital. All-cause mortality, the study’s primary endpoint, was significantly lower in the CCM group than in the control group (39% versus 71%, respectively; P = 0.001). In a subgroup of patients with baseline ejection fractions of between 25% and 40%, heart failure hospitalizations were also significantly lower in those who received CCM than in those who did not (36% versus 80%, respectively; P < 0.001). The occurrence of heart failure hospitalization showed no significant difference between the CCM and control groups in the entire cohort (41% versus 49%, respectively), but was significantly lower in CCM-treated patients compared with the control patients in the subgroup analysis of those with baseline ejection fractions of between 25% and 40% (36% versus 64%; P= 0.005).

CCM was administered using the Optimizer IVs (Impulse Dynamics), a minimally invasive implantable device for the treatment of chronic heart failure. The Optimizer IVs device has been launched in Europe and in other international markets, and has been implanted in approximately 3,000 patients to date. The device is available only for investigational use in the U.S.

Sources: PR Newswire (link is external); January 14, 2016; and International Journal of Cardiology (link is external); January 5, 2016.

More Headlines

Researchers find potentially “druggable” targets
Opdivo expected to supersede Avastin as standard of care for recurrent disease
Authorities suspend further studies of cannabinoid drug
Health care leaders resist full commitment
High cost-to-benefit ratio will limit acceptance
Treatment nearly triples progression-free survival rate


Our most popular topics on